Related Experiment Videos
[Long-term follow-up after drug-eluting stents for patients with ST-segment elevation myocardial infarction: a single
Hong-bing Yan1, Yong Zhao, Jian Wang
1Capital Medical University, Beijing 100029, China. yan591204@yahoo.com.cn
Insights
Different types of drug-eluting stents (DES) show similar long-term safety and effectiveness following primary percutaneous coronary intervention (PCI). This study confirms DES as a viable option for ST-elevation myocardial infarction (STEMI) treatment.
Area of Science:
- Cardiology
- Interventional Cardiology
- Biomedical Engineering
Context:
- Primary percutaneous coronary intervention (PCI) is a crucial treatment for ST-elevation myocardial infarction (STEMI).
- Drug-eluting stents (DES) are widely used to prevent restenosis after PCI.
- Evaluating the long-term outcomes of different DES types in primary PCI is essential for clinical practice.
Purpose:
- To assess the long-term efficacy and safety of various DES types used in primary PCI for STEMI patients.
- To compare adverse events, including major adverse cardiac events (MACE) and stent thrombosis, among different DES.
- To evaluate the safety and effectiveness of anti-platelet therapy and secondary prevention strategies in conjunction with DES.
Summary:
- A single-center study included 464 patients undergoing primary PCI for STEMI between 2004 and 2008.
- No significant differences were observed in MACE, all-cause death, or major bleeding among different DES types.
- The cumulative incidence of MACE was 9.3% and stent thrombosis was 1.1%, with no significant variations between DES groups.
Impact:
- The findings suggest that different DES types yield comparable long-term results in primary PCI.
- DES are confirmed to be safe and effective for STEMI treatment when combined with appropriate anti-platelet and secondary prevention strategies.
- This study supports the use of DES in primary PCI, offering valuable insights into long-term patient outcomes and stent performance.
Objective:
To evaluate the long-term efficacy and safety of DES in the setting of primary PCI in our single center.
Methods:
From September 2004 to November 2008, 464 patients undergoing primary PCI for STEMI were included at the 28th Division in Beijing Anzhen Hospital. The adverse events were compared among different types of DES.
Results:
The major adverse cardiac events [MACE, including sudden cardiac death, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization (TVR), reinfarction and coronary artery bypass graft], all-cause death, major bleeding, anti-platelet therapy and secondary prevention of coronary heart disease of different types of DES were no significant differences. The cumulative incidence of MACE and stent thrombosis were 9.3% and 1.1% respectively, different types of DES were 9.4%, 5.1%, 5.9%, 6.6% (P = 0.483) and 3.1%, 0.0%, 0.0%, 0.0% (P = 0.092) respectively. The patients in the DES group had longer duration of dual antiplatelet therapy (average 16.2 ± 6.7 months). No major bleeding occurred in all patients with the long-term and low-dose aspirin (100 mg).
Conclusions:
Different types of DES have the same results in the setting of primary PCI, and were long-term safe and effective with a reasonable strategy for anti-platelet therapy and secondary prevention.
Related Concept Videos
01:18Endocarditis III: Medical Management
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:27Coronary Artery Disease V: Interprofessional Care